Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study.

Scandinavian journal of rheumatology·2016

Same author

EFSUMB Minimum Training Requirements for Rheumatologists Performing Musculoskeletal Ultrasound.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2013

Same author

EFSUMB minimum training requirements for rheumatologists performing musculoskeletal ultrasound.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2013

Same author

Ultrasound evaluation of fluid in knee recesses at varying degrees of flexion.

Arthritis care & research·2012

Same author

Which knee and probe position determines the final diagnosis of knee inflammation by ultrasound? Results from a European multicenter study.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2011

Same author

Problematic and positive support in relation to depression in people with rheumatoid arthritis.

Journal of health psychology·2011

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Search research articles

Related Experiment Video

Updated: May 22, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Thalidomide Celgene Corp.

¹Department of Rheumatology, Medisch Centrum Leeuwarden, Henry Dunantweg 2, 8934 AD Leeuwarden, The Netherlands. gawbruyn@worldaccess.nl

Idrugs : the Investigational Drugs Journal

|May 10, 2008

Summary

This summary is machine-generated.

Thalidomide effectively treats erythema nodosum leprosum and shows promise for aphthous ulcers in HIV patients. It also increased body weight in AIDS-related cachexia patients, though with side effects and initial viral load increase.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Related Experiment Videos

Last Updated: May 22, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Area of Science:

Immunology and Pharmacology
Oncology and Infectious Diseases

Background:

Thalidomide inhibits elevated tumor necrosis factor-alpha (TNFalpha), suggesting therapeutic potential across various inflammatory and autoimmune conditions.
Approved for erythema nodosum leprosum, thalidomide is being investigated for a spectrum of diseases including HIV/AIDS complications, rheumatoid arthritis, and cachexia.

Purpose of the Study:

To evaluate thalidomide's efficacy in treating chronic autoimmune disorders like Behcet's disease and aphthosis.
To assess thalidomide's impact on aphthous ulcerations in HIV-infected patients.
To determine thalidomide's effectiveness in managing AIDS-related cachexia and chronic diarrhea in HIV patients.

Main Methods:

Clinical trials involving randomized, double-blind, placebo-controlled designs with varying doses of thalidomide.
Phase II and III trials assessed outcomes such as ulcer reduction, body weight changes, diarrhea occurrence, and disease markers.
Studies included patient populations with HIV/AIDS, leprosy complications, rheumatoid arthritis, and cancer-related cachexia.

Main Results:

Thalidomide significantly reduced existing ulcerations and inhibited new lesion formation in Behcet's disease and aphthosis trials.
In AIDS-related cachexia, thalidomide (100 mg dose) significantly increased body weight, but higher doses led to side effects and initial viral load increase.
A trial for chronic diarrhea in HIV patients showed a reduction in diarrhea occurrence with thalidomide treatment.

Conclusions:

Thalidomide demonstrates significant therapeutic benefits for specific inflammatory and autoimmune conditions, including ulcerations and cachexia.
Careful dose selection and monitoring are crucial due to potential side effects and impact on viral load in HIV patients.
Further research is warranted to optimize thalidomide's use in managing complex diseases like HIV/AIDS and rheumatoid arthritis.